Skip to main content
SPRO
NASDAQ Life Sciences

Spero Inks $1.1B Deal for Phase 2-Ready Autoimmune Antibody

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$2.09
Mkt Cap
$126.225M
52W Low
$1.8
52W High
$3.08
52W Position info
16% above low
Off High info
32% below high
Rel. Volume info
0.7× avg
Market data snapshot near publication time

SPRO sits 16% above its 52-week low of $1.8.

Summary

Spero Therapeutics licensed global rights (ex-Greater China) to SP001, a Phase 2-ready anti-CD40L antibody, from Innovent Biologics in a deal worth up to $1.1 billion, with up to $1.05 billion in milestones and a $105 million royalty financing. The asset targets IgG4-related disease and other autoimmune conditions, with Spero planning a Phase 2 trial in Q2 2027. This marks a strategic pivot into immunology following the recent FDA approval of Utebzi. The upfront payment and milestone structure add a new pipeline catalyst without immediate dilution, though the $1.1B headline figure is heavily back-loaded. The deal diversifies Spero beyond its infectious disease focus and leverages its development capabilities.

At the time of this announcement, SPRO was trading at $2.09 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $126.2M. The 52-week trading range was $1.80 to $3.08. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

SPRO - Latest Insights

SPRO
Nov 12, 2026, 4:34 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $0.990
Real-time Price: $0.7892 info
Change: -$0.2008 (-20%) info
Market Cap: $43.232M info
SPRO
Nov 12, 2026, 4:05 PM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $1.00
Real-time Price: $0.7892 info
Change: -$0.2108 (-21%) info
Market Cap: $43.232M info
SPRO
Aug 12, 2026, 4:03 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $1.23
Real-time Price: $0.7892 info
Change: -$0.4408 (-36%) info
Market Cap: $43.232M info
SPRO
Aug 12, 2026, 4:01 PM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $1.23
Real-time Price: $0.7892 info
Change: -$0.4403 (-36%) info
Market Cap: $43.232M info
SPRO
Jul 14, 2026, 6:30 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $2.11
Real-time Price: $0.7892 info
Change: -$1.32 (-63%) info
Market Cap: $43.232M info